Hedgehog	0	8	B-Gene_or_gene_product
signaling	9	18	O
in	19	21	O
the	22	25	O
murine	26	32	B-Organism
melanoma	33	41	B-Pathological_formation
microenvironment	42	58	O
.	58	59	O

The	61	64	O
Hedgehog	65	73	B-Gene_or_gene_product
intercellular	74	87	O
signaling	88	97	O
pathway	98	105	O
regulates	106	115	O
cell	116	120	B-Cell
proliferation	121	134	O
and	135	138	O
differentiation	139	154	O
.	154	155	O

This	156	160	O
pathway	161	168	O
has	169	172	O
been	173	177	O
implicated	178	188	O
to	189	191	O
play	192	196	O
a	197	198	O
role	199	203	O
in	204	206	O
the	207	210	O
pathogenesis	211	223	O
of	224	226	O
cancer	227	233	O
and	234	237	O
in	238	240	O
embryonic	241	250	O
blood	251	256	B-Multi-tissue_structure
vessel	257	263	I-Multi-tissue_structure
development	264	275	O
.	275	276	O

In	277	279	O
the	280	283	O
current	284	291	O
study	292	297	O
,	297	298	O
Hedgehog	299	307	B-Gene_or_gene_product
signaling	308	317	O
in	318	320	O
tumor	321	326	B-Pathological_formation
related	327	334	O
vasculature	335	346	B-Multi-tissue_structure
and	347	350	O
microenvironment	351	367	O
was	368	371	O
examined	372	380	O
using	381	386	O
human	387	392	B-Cell
umbilical	393	402	I-Cell
vein	403	407	I-Cell
endothelial	408	419	I-Cell
cells	420	425	I-Cell
and	426	429	O
B16F0	430	435	B-Cell
(	436	437	O
murine	437	443	B-Organism
melanoma	444	452	B-Pathological_formation
)	452	453	O
tumors	454	460	B-Pathological_formation
models	461	467	O
.	467	468	O

Use	469	472	O
of	473	475	O
exogenous	476	485	O
Sonic	486	491	B-Gene_or_gene_product
hedgehog	492	500	I-Gene_or_gene_product
(	501	502	O
Shh	502	505	B-Gene_or_gene_product
)	505	506	O
peptide	507	514	O
significantly	515	528	O
increased	529	538	O
BrdU	539	543	B-Drug_or_compound
incorporation	544	557	O
in	558	560	O
endothelial	561	572	B-Cell
cells	573	578	I-Cell
in	579	581	O
vitro	582	587	O
by	588	590	O
a	591	592	O
factor	593	599	O
of	600	602	O
2	603	604	O
(	605	606	O
P	606	607	O
less	609	613	O
than	614	618	O
0	620	621	O
.	621	622	O
001	622	625	O
)	625	626	O
.	626	627	O

The	628	631	O
Hedgehog	632	640	B-Gene_or_gene_product
pathway	641	648	O
antagonist	649	659	O
cyclopamine	660	671	B-Drug_or_compound
effectively	672	683	O
reduced	684	691	O
Shh	692	695	B-Gene_or_gene_product
-	695	696	O
induced	696	703	O
proliferation	704	717	O
to	718	720	O
control	721	728	O
levels	729	735	O
.	735	736	O

To	737	739	O
study	740	745	O
Hedgehog	746	754	B-Gene_or_gene_product
signaling	755	764	O
in	765	767	O
vivo	768	772	O
a	773	774	O
hind	775	779	B-Pathological_formation
limb	780	784	I-Pathological_formation
tumor	785	790	I-Pathological_formation
model	791	796	O
with	797	801	O
the	802	805	O
B16F0	806	811	B-Cell
cell	812	816	I-Cell
line	817	821	I-Cell
was	822	825	O
used	826	830	O
.	830	831	O

Treatment	832	841	O
with	842	846	O
25	847	849	O
mg	850	852	O
/	852	853	O
kg	853	855	O
cyclopamine	856	867	B-Drug_or_compound
significantly	868	881	O
attenuated	882	892	O
BrdU	893	897	B-Drug_or_compound
incorporation	898	911	O
in	912	914	O
tumor	915	920	B-Cell
cells	921	926	I-Cell
threefold	927	936	O
(	937	938	O
P	938	939	O
less	941	945	O
than	946	950	O
0	952	953	O
.	953	954	O
001	954	957	O
)	957	958	O
,	958	959	O
in	960	962	O
tumor	963	968	B-Pathological_formation
related	969	976	O
endothelial	977	988	B-Cell
cells	989	994	I-Cell
threefold	995	1004	O
(	1005	1006	O
P	1006	1007	O
=	1008	1009	O
0	1010	1011	O
.	1011	1012	O
004	1012	1015	O
)	1015	1016	O
,	1016	1017	O
and	1018	1021	O
delayed	1022	1029	O
tumor	1030	1035	B-Pathological_formation
growth	1036	1042	O
by	1043	1045	O
4	1046	1047	O
days	1048	1052	O
.	1052	1053	O

Immunohistochemistry	1054	1074	O
revealed	1075	1083	O
that	1084	1088	O
the	1089	1092	O
Hedgehog	1093	1101	B-Gene_or_gene_product
receptor	1102	1110	O
Patched	1111	1118	B-Gene_or_gene_product
was	1119	1122	O
localized	1123	1132	O
to	1133	1135	O
the	1136	1139	O
tumor	1140	1145	B-Pathological_formation
stroma	1146	1152	I-Pathological_formation
and	1153	1156	O
that	1157	1161	O
B16F0	1162	1167	B-Cell
cells	1168	1173	I-Cell
expressed	1174	1183	O
Shh	1184	1187	B-Gene_or_gene_product
peptide	1188	1195	O
.	1195	1196	O

Furthermore	1197	1208	O
,	1208	1209	O
mouse	1210	1215	B-Organism
embryonic	1216	1225	B-Cell
fibroblasts	1226	1237	I-Cell
required	1238	1246	O
the	1247	1250	O
presence	1251	1259	O
of	1260	1262	O
B16F0	1263	1268	B-Cell
cells	1269	1274	I-Cell
to	1275	1277	O
express	1278	1285	O
Patched	1286	1293	B-Gene_or_gene_product
in	1294	1296	O
a	1297	1298	O
co	1299	1301	O
-	1301	1302	O
culture	1302	1309	O
assay	1310	1315	O
system	1316	1322	O
.	1322	1323	O

These	1324	1329	O
studies	1330	1337	O
indicate	1338	1346	O
that	1347	1351	O
Shh	1352	1355	B-Gene_or_gene_product
peptide	1356	1363	O
produced	1364	1372	O
by	1373	1375	O
melanoma	1376	1384	B-Cell
cells	1385	1390	I-Cell
induces	1391	1398	O
Patched	1399	1406	B-Gene_or_gene_product
expression	1407	1417	O
in	1418	1420	O
fibroblasts	1421	1432	B-Cell
.	1432	1433	O

To	1434	1436	O
study	1437	1442	O
tumor	1443	1448	B-Pathological_formation
related	1449	1456	O
angiogenesis	1457	1469	O
a	1470	1471	O
vascular	1472	1480	O
window	1481	1487	O
model	1488	1493	O
was	1494	1497	O
used	1498	1502	O
to	1503	1505	O
monitor	1506	1513	O
tumor	1514	1519	B-Pathological_formation
vascularity	1520	1531	O
.	1531	1532	O

Treatment	1533	1542	O
with	1543	1547	O
cyclopamine	1548	1559	B-Drug_or_compound
significantly	1560	1573	O
attenuated	1574	1584	O
vascular	1585	1593	B-Multi-tissue_structure
formation	1594	1603	O
by	1604	1606	O
a	1607	1608	O
factor	1609	1615	O
of	1616	1618	O
2	1619	1620	O
.	1620	1621	O
5	1621	1622	O
(	1623	1624	O
P	1624	1625	O
less	1627	1631	O
than	1632	1636	O
0	1638	1639	O
.	1639	1640	O
001	1640	1643	O
)	1643	1644	O
and	1645	1648	O
altered	1649	1656	O
vascular	1657	1665	B-Multi-tissue_structure
morphology	1666	1676	O
.	1676	1677	O

Furthermore	1678	1689	O
,	1689	1690	O
cyclopamine	1691	1702	B-Drug_or_compound
reduced	1703	1710	O
tumor	1711	1716	B-Multi-tissue_structure
blood	1717	1722	I-Multi-tissue_structure
vessel	1723	1729	I-Multi-tissue_structure
permeability	1730	1742	O
to	1743	1745	O
FITC	1746	1750	B-Drug_or_compound
labeled	1751	1758	O
dextran	1759	1766	B-Drug_or_compound
while	1767	1772	O
having	1773	1779	O
no	1780	1782	O
effect	1783	1789	O
on	1790	1792	O
normal	1793	1799	O
blood	1800	1805	B-Multi-tissue_structure
vessels	1806	1813	I-Multi-tissue_structure
.	1813	1814	O

These	1815	1820	O
studies	1821	1828	O
suggest	1829	1836	O
that	1837	1841	O
Hedgehog	1842	1850	B-Gene_or_gene_product
signaling	1851	1860	O
regulates	1861	1870	O
melanoma	1871	1879	B-Pathological_formation
related	1880	1887	O
vascular	1888	1896	B-Multi-tissue_structure
formation	1897	1906	O
and	1907	1910	O
function	1911	1919	O
.	1919	1920	O

